Idelalisib may have the potential to increase radiotherapy side effects

INTRODUCTION: Idelalisib is approved for the treatment of relapsed chronic lymphocytic leukemia together with Rituximab and for monotherapy of follicular B-cell non-Hodgkin’s lymphoma and small lymphocytic lymphoma. It is a potent and selective phosphatidylinositol 3-kinase-δ (PI3K-δ) inhibitor. PI3...

Descripción completa

Detalles Bibliográficos
Autores principales: Gryc, Thomas, Putz, Florian, Goerig, Nicole, Ziegler, Sonia, Fietkau, Rainer, Distel, Luitpold V., Schuster, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490234/
https://www.ncbi.nlm.nih.gov/pubmed/28659152
http://dx.doi.org/10.1186/s13014-017-0827-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490234/
https://www.ncbi.nlm.nih.gov/pubmed/28659152
http://dx.doi.org/10.1186/s13014-017-0827-7

Ejemplares similares